Job Trends
Looking for a biopharma job in Illinois? Check out these top five companies hiring life sciences professionals like you.
Labor Market Reports
Year-over-year BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the first quarter of 2025.
The 9% average salary increase from 2023 to 2024 was the largest for life sciences professionals since 2021. Several factors could be behind the spike, including companies providing higher pay because bonuses and stock compensation went down.
Now Hiring
Looking for a biopharma job in San Francisco? Check out the BioSpace list of 10 companies hiring life sciences professionals like you.
Although the job market did not pick up in April, layoffs were down year over year and month over month, according to BioSpace tallies. Meanwhile, Amgen, Novartis, Regeneron and Roche announced U.S. manufacturing investments that are sparking job creation.
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
Career Advice
If you’re questioning which types of leaders you get along with the best, or you’re just wondering what types of leaders exist, you’re in the right place. Here’s a quick breakdown.
THE LATEST
Lycia will be receiving a $35 million upfront payment from Lilly and is eligible for over $1.6 billion in potential milestone payments.
Pfizer Chief Executive Officer Albert Bourla tapped Aamir Malik to serve as the company’s chief business innovation officer.
The Bay State biopharma industry continues to boom, even during the height of a global pandemic that has caused an economic downturn in other business sectors.
Merck has announced its vaxneuvance for pneumococcal disease in infants and has met key safety, tolerability, and immunogenicity endpoints in the first 30 days.
Rubix Life Sciences has launched a dedicated therapeutics division to focus on infectious and neurodegenerative diseases.
Novartis reported that its Kymriah failed to hit its primary endpoint in the Phase III BELINDA trial in aggressive B-cell non-Hodgkin lymphoma after relapse or lack of response to first-line treatment.
Many expect the full approval will lead to vaccine mandates, as that was one of the obstacles to it for many organizations.
A J&J spokesperson said yesterday that it is collecting more data on whether a booster shot is necessary.
Specifically, the new approval was for adults with dMMR recurrent or advanced solid tumors who have progressed on or after previous treatment and who have no satisfactory alternatives.
As COVID-19 surges to earlier pandemic levels in the U.S., federal health officials are expected to authorize a third booster shot eight months after receiving the second of the Moderna and Pfizer-BioNTech vaccines, and probably the Johnson & Johnson vaccine as well.